Entity

Time filter

Source Type


Scheffers I.J.M.,Maastricht University | Kroon A.A.,Maastricht University | Schmidli J.,University of Bern | Jordan J.,Hannover Medical School | And 11 more authors.
Journal of the American College of Cardiology | Year: 2010

Objectives This study assessed the safety and efficacy of a novel implantable device therapy in resistant hypertension patients. Background Despite the availability of potent antihypertensive drugs, a substantial proportion of patients remain hypertensive. A new implantable device (Rheos system, CVRx, Inc., Minneapolis, Minnesota) that activates the carotid baroreflex may help these patients. Methods Forty-five subjects with systolic blood pressure ≥160 mm Hg or diastolic ≥90 mm Hg despite at least 3 antihypertensive drugs were enrolled in a prospective, nonrandomized feasibility study to assess whether Rheos therapy could safely lower blood pressure. Subjects were followed up for as long as 2 years. An external programmer was used to optimize and individualize efficacy. Results Baseline mean blood pressure was 179/105 mm Hg and heart rate was 80 beats/min, with a median of 5 antihypertensive drugs. After 3 months of device therapy, mean blood pressure was reduced by 21/12 mm Hg. This result was sustained in 17 subjects who completed 2 years of follow-up, with a mean reduction of 33/22 mm Hg. The device exhibited a favorable safety profile. Conclusions The Rheos device sustainably reduces blood pressure in resistant hypertensive subjects with multiple comorbidities receiving numerous medications. This unique therapy offers a safe individualized treatment option for these high-risk subjects. This novel approach holds promise for patients with resistant hypertension and is currently under evaluation in a prospective, placebo-controlled clinical trial. © 2010 American College of Cardiology Foundation. Source


Woehrle H.,Sleep and Ventilation Center Blaubeuren | Woehrle H.,ResMed | Oldenburg O.,Heart and Diabetes Center North Rhine Westphalia | Arzt M.,University of Regensburg | And 4 more authors.
BMC Cardiovascular Disorders | Year: 2014

Background: The objective of the SCHLA-HF registry is to investigate the prevalence of sleep-disordered breathing (SDB) in patients with chronic heart failure with reduced left ventricular systolic function (HF-REF) and to determine predictors of SDB in such patients.Methods: Cardiologists in private practices and in hospitals in Germany are asked to document patients with HF-REF into the prospective SCHLA-HF registry if they meet predefined inclusion and exclusion criteria. Screening was started in October 2007 and enrolment was completed at the end of May 2013. After enrolment in the registry, patients are screened for SDB. SDB screening is mainly undertaken using the validated 2-channel ApneaLink™ device (nasal flow and pulse oximetry; ResMed Ltd., Sydney, Australia). Patients with a significant number of apneas and hypopneas per hour recording time (AHI ≥15/h) and/or clinical symptoms suspicious of SDB will be referred to a cooperating sleep clinic for an attended in-lab polysomnography with certified scoring where the definite diagnosis and, if applicable, the differentiation between obstructive and central sleep apnea will be made. Suggested treatment will be documented.Discussion: Registries play an important role in facilitating advances in the understanding and management of cardiovascular disease. The SCHLA-HF registry will provide consistent data on a large group of patients with HF-REF that will help to answer questions on the prevalence, risk factors, gender differences and stability of SDB in these patients by cross-sectional analyses. Further insight into the development of SDB will be gained by extension of the registry to include longitudinal data. © 2014 Woehrle et al.; licensee BioMed Central Ltd. Source


Furukawa N.,Heart and Diabetes Center North Rhine Westphalia
Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | Year: 2015

ABSTRACT: An 81-year-old man with high-grade aortic valve stenosis and status post–coronary artery bypass grafting and supracoronary replacement of the ascending aorta was referred for transcatheter aortic valve implantation. He was in New York Heart Association class III and had dyspnea. After appropriate screening, we implanted a 29-mm SAPIEN XT valve (Edwards Lifesciences, Irvine, CA USA) through a transapical approach because of severe peripheral arterial occlusive disease. Postinterventional aortography revealed correct positioning and function of the valve and free coronary ostia but contrast extravasation in the vicinity of the interposed vascular prosthesis, resulting in severe luminal narrowing. We chose to manage the stenosis with an endovascular stent. After stenting, extravascular compression was markedly reduced, and the pressure gradient disappeared. The patient was discharged home on the 20th postoperative day. Three months later, computed tomography depicted correct positioning of both grafts. The patient’s general health is good, and he is now in New York Heart Association class II. This case illustrates a complication of transcatheter aortic valve implantation specific for patients with an ascending aortic graft. Although stenting may be a good solution, as depicted by this case, self-expanding transcatheter aortic valves should be preferred in patients with ascending aortic grafts to avoid the described complication. ©2015 by the International Society for Minimally Invasive Cardiothoracic Surgery. Source


Furukawa N.,Heart and Diabetes Center North Rhine Westphalia | Hansky B.,Heart and Diabetes Center North Rhine Westphalia | Niedermeyer J.,Krankenhaus Bad Oeynhausen | Gummert J.,Heart and Diabetes Center North Rhine Westphalia | Renner A.,Heart and Diabetes Center North Rhine Westphalia
Journal of Cardiothoracic Surgery | Year: 2011

Solitary fibrous tumor of the pleura is a rare mesenchymal tumor, representing less than 5% of all neoplasms associated with the pleura. A 57-year-old man had general malaise without chest symptoms for 1 month. A chest roentgenogram and computed tomography showed a giant mass in the left thorax. Although the tumor compressed the descending aorta and other mediastinal structures strongly, thereby shifting them to the right side, the patient had no symptoms except malaise. The tumor was successfully resected via two separate thoracotomies. The tumor was measured (20 cm × 19 cm × 15 cm) and weighed (2150 g). The tumor was histologically and immunohistochemically diagnosed as benign. Although SFT is benign, a long follow-up period is essential as even patients with complete resection are at risk of recurrence many years after surgery. © 2011 Furukawa et al; licensee BioMed Central Ltd. Source


Weile J.,Heart and Diabetes Center North Rhine Westphalia | Seibold E.,University of Federal Defense Munich | Knabbe C.,Robert Bosch GmbH | Kaufmann M.,Heart and Diabetes Center North Rhine Westphalia | And 2 more authors.
Emerging Infectious Diseases | Year: 2013

We describe a case of human tularemia caused by Francisella tularensis subsp. holarctica in a stem cell transplant recipient with chronic graft-versus-host disease who was receiving levofloxacin prophylaxis. The infection was characterized by pneumonia with septic complications. The patient was successfully treated with doxycycline. Source

Discover hidden collaborations